In an exclusive interview with *Pharma Industrial India*, Syed Ahmed, our CEO shares how the company is revolutionizing vaccine manufacturing through automation and digitalization. By integrating advanced technologies, TechInvention is driving efficiency and precision in the production process, ensuring high-quality outcomes at scale. He discusses how these innovations position TechInvention at the forefront of global vaccine manufacturing, enhancing accessibility and accelerating timelines to meet global health demands.
LEAP India Startup Summit 2024 Publication - Expert View; Syed Ahmed Our CEO discusses the company’s innovative approach to solving global healthcare challenges in an exclusive interview with *Dun & Bradstreet* for the LEAP India Startup Summit. Focusing on TechInvention’s journey from startup to an internationally recognized player in biopharmaceuticals, Mr Syed Ahmed highlights the company’s commitment to leveraging cutting-edge technologies in vaccine development and diagnostics.
Website link : https://www.dnb.co.in/events/leapindiastartupsummit/textinterview.aspx
We have been appointed by the Botswana Vaccine Institute (BVI) to supervise the creation of a state-of-the-art, cGMP-compliant veterinary vaccine manufacturing unit in Gaborone, Botswana. This project, set to be operational by 2026, will enhance BVI's capacity and quality of veterinary vaccines, meeting stringent global standards and expanding their market reach.
We are proud to announce its D-U-N-S® registration with Dun & Bradstreet, further solidifying its commitment to operational excellence and global credibility. This certification reinforces our standing as a trusted partner in the biopharmaceutical industry. With its registered address in Mumbai, India, TechInvention continues to lead innovations in vaccine manufacturing and diagnostics, adhering to the highest standards of business transparency and compliance
We are proud to announce that we have been honoured with the prestigious 'Start-up 50: The Trailblazers Award' from Dun & Bradstreet at the LEAP India Startup Summit 2024. This recognition highlights our commitment to innovation, quality, and sustainable growth in the biotech sector. Our self-funded, cash-positive business model, focused on prevention, detection, and treatment of diseases through vaccines, diagnostics, and novel biotherapeutics, has set us apart in the global market.
Our CEO, Syed Ahmed, delves into the company's groundbreaking initiatives in biopharmaceutical manufacturing in an exclusive interview with PharmaBiz magazine. Interviewed by Shardul Nautiyal, the conversation focuses on TechInvention’s strategic efforts to expand global vaccine access through its Global Capability Mapping Collaboration (GCMC). Ahmed emphasizes how GCMC brings together key stakeholders to address gaps in manufacturing capacity and ensures scalable, cost-effective vaccine production.
Website link : https://www.pharmabiz.com/
TechInvention breaks ground for their facility, the ‘Global Collaborative Centre for Medical Countermeasures’ (GCMC), a pivotal advancement in global health security and pandemic preparedness. Recognized at the 2nd World Local Production Forum in the Hague recently, GCMC is in alignment with global health initiatives and our own ‘National Biotechnology Development Strategy’ of India.
The eco-friendly center will serve as a vital resource for both public and private organizations worldwide, streamlining the transition from R&D to GMP-scale production with the required regulatory approvals; it encompasses the entire vaccine development cycle, IVDs, and biotherapeutics for the human and veterinary segments that go into enabling ‘One Health’.
We are glad to initiate work on GCMC, a priority project to tackle the looming crisis of prevailing, emerging, and re-emerging infectious diseases with a compelling need to collaborate and accelerate.
Our CEO spoke on the topic of ‘Decarbonizing Veterinary Vaccine Manufacturing & Supply Chain’ at the ‘Animal Health Conclave’ themed ‘Shaping Animal Health sector with Innovative Vaccine & Precision diagnostics’ organized event by the Department of Animal Husbandry and Dairying, Government of India in association with Indian Immunological’s Ltd.
Our senior Scientist Dr Sarmad Hanif was delighted to have attended the launch of the UCL- University of Oxford, Future Vaccine Manufacturing Research Hub (Vax-Hub)'s Vax-Hub Sustainable, which took place in London on December 8 2023.
Our CEO Syed Ahmed and Senior research scientist Dr. Sarmad Hanif presented our Men B vaccine in development at the recent BactiVac Conference in Birmingham!
We had the distinct honor of hosting a distinguished delegation from the Commonwealth of Independent States (CIS). Given the fruitful deliberations and interactions, it is with great respect that we acknowledge the growth of the biotech manufacturing sector in the CIS region.
We are glad to announce that our clinical trials team lead, Ms. Bhakti Chavan a survivor of XDR-TB, has been selected as a member of the First Taskforce of Antimicrobial Resistance (AMR) survivors by the World Health Organization (WHO). She is the only Indian to be selected to be a part of the 12-member team!
Our CEO participated and spoke at the ADB-CoRE Vaccine Seminar. At the heart of the ADB-CoRE Vaccine Seminar lies an incredible opportunity to connect with brilliance from every corner of the world. The ADB-CoRE Seminar isn't just about discussions – it's a platform to build meaningful connections that drive positive change. We are excited to engage, collaborate, and amplify impact that resonate far beyond the seminar!
Our CEO discussed our research work on Recombinant Phage encoded Lysin in the management of Uropathogenic E.coli during the conference on Drug Development to meet the challenge of Antimicrobial resistance which was organized by the American Society of Microbiology along with European society of clinical microbiology and infectious diseases.
Our team was honored to have met with Dr. J V Parekh, a pioneer in dairy technologies and an active consultant to multiple dairy plants globally. We are glad to have the opportunity to venture into an association with him to take our mission of One Health forward!
Our CEO had the privilege to participate and discuss the pivotal role that Indian startups are playing in the global vaccine domain during the 2nd Edition of India Vaccine Leaders Conclave which was themed “Building Resilient Vaccine Ecosystems.
Our CEO attended the G20 Health ministers' meet focused on pandemic preparedness, antimicrobial resistance, bridging the gap in essential healthcare and the solution that is One Health.
We proudly announce our successful attainment of ISO 9001:2015 certification. This achievement reinforces our commitment to delivering exceptional quality and customer satisfaction. It is a true testament to our unwavering commitment to deliver excellence at par.
It was indeed a remarkable meeting between our CEO Syed Ahmed and the esteemed UK Minister of Science, Research and Innovation Dr. George Freeman along with other distinguished members from the biotech and pharmaceutical industry. Their discussion centered around fostering stronger collaboration opportunities between UK and India, opening doors to groundbreaking advancements in the healthcare field. An exciting era of transformative solutions awaits!
Team Techinvention would like to thank the Department of Pharmaceuticals and Invest India for inviting our CEO, Syed Ahmed, to present our perspective to the esteemed panel of dignitaries and industry colleagues. The deliberations were highly insightful, and we firmly believe that such initiatives would contribute in a big way towards enabling Atmanirbhar Bharat for Vaccine manufacturing. presentation.
On June 3 rd 2023, Techinvention’s CEO Syed Ahmed attended the G20 Department of
Pharmaceuticals, Government of India, PATH, and CEPI co-branded event on ‘Global Vaccine
Research Collaborative’.
The Forum, which was well attended and participated by global thought leaders, subject matter
experts, major GOI, CEPI, and PATH office bearers, provided excellent insights and concrete ideas
that could help us proceed towards the framework for the 100 days CEPI goal.
At the Africa Health ExCon Summit in Cairo, Egypt, in August, Techinvention’s CEO Syed
Ahmed, had the honour of taking the stage alongside eminent experts in the field of vaccines and
speaking in front of an august audience.
He presented the GennVax Strategy for local vaccine production "For Africans by Africans" in his
presentation.
Techinvention launches Euvichol-Plus, the world’s first and only oral cholera vaccine (OCV), in
low-density polyethylene (LDPE) unidose pack in India.
Read the coverage here
TechInvention Lifecare Pvt. Ltd entered into a strategic collaboration with Reagent IVD Resources
Pvt. Ltd. (RIVDR), a Jaipur-based diagnostics-focused start-up, for the development and
manufacturing of a comprehensive range of diagnostics. The portfolio would encompass human as
well as veterinary segments for global supplies.
Read the coverage here
WHO observes World Immunization Week from 24-30 April in order to raise awareness about the need for immunization.
Immunization is one of the most important factors in working towards achieving the bigger picture of one health.
Taking into account the World Immunization Week initiative and public interest, TechInvention Lifecare Pvt. Ltd. and BioGRIT Technologies Inc. are pleased to present the "Let's Win with Vaccines" awareness illustrations.
WHO observes World Antimicrobial Awareness Week from 18–24 November , to raise awareness about the pressing issue that is AMR.
Taking an initiative in the public interest, we are pleased to present the "Let's Win with Vaccines" awareness illustrations.
WHO observes World Antimicrobial Awareness Week from 18–24 November , to raise awareness about the pressing issue that is AMR. Taking an initiative in the public interest , TechInvention hosted webinar in association with EBPMN and IBRC, hosted by IBLoT titled “Antimicrobial Resistance and One Health: Stakes Involved and Ways Forward,” an initiative with key opinion leaders (KOLs) of the industry. Read more
TechInvention was amongst the few startups from 61,000 startups to be selected to make policy recommendations to the prime minister under the Theme ‘Nudging the DNA’ as of an initiative by DPIIT, startup India, and Invest India in accordance with the startup innovation week that was celebrated from 10th to 16th January under the grand celebration of Azadi ka Amrit Mahotsav.
Positive outcomes for TechInvention’s indigenously developed recombinant subunit SARS-CoV-2 vaccine is the news of the moment! Read the story in Financial Express or download the press release.
TechInvention’s collaboration with Eubiologics, South Korea, to bring the world’s first and only oral cholera vaccine in a LDPE unidose pack to India made the headlines! Read the coverage in Express Pharma, ET Healthworld, MedIndia, Outlook Magazine and Yahoo Finance.
We were recently featured in Saif Talk magazine.
Read the article here (PDF).
SwiftNLift Magazine counted us among the top 10 Best Biotechnology Companies of 2020. Read the interview with our founder (PDF).
TechInvention is honoured to join the fight against Covid-19. We’re funding BioNest-PU’s research into the diagnosis and prophylaxis of the novel SARS-CoV2. Read the article.
Startup City Magazine interviewed our founder Syed S Ahmed for their Best Company Of The Year 2019 series. Read the interview (PDF).
© 2023 TechInvention. Developed by Scivision Solutions Pvt. Ltd.